Last reviewed · How we verify
IN10018 in combination with RNK08954
IN10018 in combination with RNK08954 is a Small molecule drug developed by InxMed (Shanghai) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | IN10018 in combination with RNK08954 |
|---|---|
| Sponsor | InxMed (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IN10018 in combination with RNK08954 CI brief — competitive landscape report
- IN10018 in combination with RNK08954 updates RSS · CI watch RSS
- InxMed (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about IN10018 in combination with RNK08954
What is IN10018 in combination with RNK08954?
IN10018 in combination with RNK08954 is a Small molecule drug developed by InxMed (Shanghai) Co., Ltd..
Who makes IN10018 in combination with RNK08954?
IN10018 in combination with RNK08954 is developed by InxMed (Shanghai) Co., Ltd. (see full InxMed (Shanghai) Co., Ltd. pipeline at /company/inxmed-shanghai-co-ltd).
What development phase is IN10018 in combination with RNK08954 in?
IN10018 in combination with RNK08954 is in Phase 1.